Access of recombinant proteins to the retina following intravitreal administration is poorly understood. A study was conducted in male Rhesus monkeys (15 to 28 mo of age; 2.8-3.3 kg) in order to compare the intraocular tissue distribution, pharmacokinetics, and safety of 125 Iodine (I)-labeled full-length humanized rhuMAb HER2 antibody (148 kD) and of 125 I-labeled humanized rhuMAb vascular endothelial growth factor Fab antibody (48.3 kD) following bilateral bolus intravitreal injection on day 0 (5 animals/group). The dose administered to each eye was 25 &mu;g (9-10 &mu;Ci) in 50 &mu;l. Animals were euthanatized on day 0 (1 hr postdose) and on days 1, 4, 7, and 14. Safety assessment included direct ophthalmoscopy, intraocular pressure measurements, clinical observations, body weight, and hematology and clinical chemistry panels. Blood and vitreous samples were collected daily (blood only) and at necropsy for pharmacokinetics and analysis for antibodies to the test materials; the ocular tissue distribution of the test material was evaluated by microautoradiography. All animals completed the study. Microautoradiography demonstrated that the full-length antibody did not penetrate the inner limiting membrane of the retina at any of the time points examined. In contrast, the Fab antibody fragment diffused through the neural retina to the retinal pigment epithelial layer at the 1-hr time point and persisted in this location for up to 7 days. Systemic exposure to test material was low but variable: the highest plasma concentration of the full-length antibody was 20.3 ng/ml, whereas plasma concentrations for the Fab antibody remained below the limit of quantitation (i.e., <7.8 ng/ml). An immune response to the test material was not evident in either treatment group. The half-life in vitreous was 5.6 days for the full-length antibody and 3.2 days for the Fab antibody. The shorter intravitreal half-life of the Fab antibody is related to its smaller size and its significant diffusion through the retinal layers. The differences in pharmacokinetics and tissue distribution that are noted between the full-length and Fab antibodies in this study identify potential therapeutic approaches that may be exploited in specific disease conditions.
INTRODUCTION
The development of a vascular supply is a fundamental requirement for organ development and differentiation during embryogenesis as well as for wound healing and reproductive functions in the adult (7) . Angiogenesis is also implicated in the pathogenesis of a variety of disorders, including proliferative diabetic retinopathy (PDR), age-related macular degeneration (AMD), neoplasia, rheumatoid arthritis, and psoriasis (7, 8) .
The search for positive regulators of angiogenesis has yielded several candidates, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-a, TGF-~3, hepatocyte growth factor, tumor necrosis factor-cx, angiogenin, interleukin-8, etc. (7) . Studies in several laboratories over the last few years have elucidated the pivotal role of vascular endothelial growth factor (VEGF) and its receptors in the regulation of nor-mal and pathologic angiogenesis (6) . The finding that the loss of even 1 VEGF allele results in embryonic lethality demonstrates the critical role of this growth factor in the development and differentiation of the vascular system (5) . VEGF has been shown to be a key mediator of tumor angiogenesis (10) ; furthermore, VEGF has been implicated in the pathogenesis of intraocular neovascularization. Increased VEGF concentrations in the aqueous and vitreous of patients with PDR have been described (2) . Direct evidence supporting the hypothesis that VEGF is a mediator of intraocular neovascularization has been demonstrated in a primate model of iris neovascularization, and intraocular administration of anti-VEGF antibodies dramatically inhibits the neovascularization that follows central retinal vein occlusion in this model (1) .
Neovascularization is also a major cause of visual loss in AMD, the leading cause of blindness in elderly patients (4) . A significant percentage of patients with AMD (-~-10°70) manifest the neovascular (exudative) form of the disease. In this condition, new vessels arise from the choriocapillaris, penetrate Bruch's membrane, and invade the outer retina. Leakage and bleeding from these vessels may lead to retinal detachment, with damage to the macula and subsequent loss of central vision (4) . Because of the proximity of these vessels to the macula, laser photocoagulation or surgery are of limited therapeutic value. Recent immunohistochemical studies in surgically resected choroidal neovascular membranes from AMD patients have demonstrated VEGF protein expression in transdifferentiated retinal pigment epithelial cells in the highly vascularized regions of the membranes, suggesting a role for VEGF in the pathogenesis of AMD-related choroidal neovascularization (13) .
Access of therapeutic proteins to the retina following intravitreal administration is poorly understood. Although treatment with a full-length antibody is possible, other molecular forms, such as a Fab antibody, may offer advantages for targeted delivery to specific retinal layers in some disease conditions. The objective of this study was to compare the retinal distribution, pharmacokinetics, and safety of a full-length humanized antibody (I25Iodine (I)-rhuMAb HER2) and a humanized Fab antibody ('25I_ rhuMAb VEGF Fab) in Rhesus monkeys following bilateral intravitreal bolus injection. The selection of the specific full-length and Fab antibodies that were used in this study was based upon (a) their relative size differential (148 versus 48.3 kD, respectively), (b) the availability of pure, fully characterized material of sufficient quantity for radiolabeling, and (c) the availability of inhouse assays for analytes and anti-analyte antibodies.
MATERIALS AND METHODS
Test Material Preparation and Characterization. Recombinant humanized monoclonal antibody against HER2 (rhuMAb HER2 [Herceptin~]; Genentech, Inc.) and recombinant humanized Fab antibody against VEGF (rhuMAb VEGF Fab; Genentech, Inc.) were radiolabeled using a modification of the chloramine-T catalyzed iodination method (9) . Radiolabeled test materials were mixed with corresponding unlabeled test material in order to provide a final dose of 25 Rg protein (9-10 ~Ci) in 50 >1 for each eye. The calculated specific activity of the dose solution was 0.400 ~Ci/~g for the full-length antibody and 0.445 ~Ci/~g for the Fab antibody. Both dosing solutions showed greater than 99% trichloroacetic acid (TCA) precipitability. Labeled test material was assayed for endotoxin (LAL method, Genentech Assay Services); endotoxin levels were <0.005 EU/ml for the full-length antibody and <0.03 EU/ml for the Fab antibody.
Animals. Ten healthy juvenile male Rhesus macaques, 15 to 28 mo of age (2.8-3.3 kg), were selected for the study based on physical examination, hematology and clinical chemistry screens, fecal cultures, ophthalmologic evaluation, and prestudy plasma sample analysis. All animals were identified with a unique number tattoo. The animals were fed Purina Monkey Chow (25% protein, preanalyzed) supplemented with fruit, and drinking water was provided ad libitum. Animals were individually housed in stainless-steel metabolism cages, in compliance with established standards of the Federal Animal Welfare Act and the Institute for Laboratory Animal Resource. The animals were randomly assigned to 2 treatment groups (n = 5 animals/group). Following intravitreal administration of the test materials (day 0), animals were observed twice daily for routine health problems and physical signs related to injection of the labeled test material. Terminal body weights, ophthalmic examinations, and intraocular pressure (IOP) were recorded prior to necropsy on days 0 (1 hr postdose), 1, 4, 7, and 14 (n = 1 animal/time point/group). Intravitreal Injections. The animals were immobilized with an intramuscular injection of ketamine (10 mg/kg; Fort Dodge Labs, Fort Dodge, IA), topical anesthesia was induced with 2 drops of 0.5% Proparacaine HCI (Bausch & Lomb, Tampa, FL), and predose IOP was recorded as described below. Labeled test material was injected in the inferotemporal pars plana region, 3-6 mm caudal to the limbus, as follows: while aiming toward the mid-vitreous cavity, a 28-gauge 1/a-inch needle was inserted to the hub, and 50 >1 was injected slowly, with the bevel of the needle directed away from the retina. The needle was withdrawn immediately, and IOP was recorded. Each eye received 25 Rg protein per eye, for a total dose of 50 Rg per animal. Artificial Tears°3 ointment (Rugby, Rockville Center, NY) was applied to each eye after the injection.
Ophthalmologic Evaluations. These evalautions were performed at the time of animal selection, immediately prior to dosing, immediately after dosing, and at necropsy, while the animals were immobilized with ketamine. Direct Fundic Examination: Pupils were dilated with 1 % Tropicamide ophthalmic solution (Bausch & Lomb, Tampa, FL) in order to facilitate fundic examination with an ophthalmoscope (Welch Allyn Medical Products, Skaneateles Falls, NY). IOP: Topical anesthesia was induced with 2 drops of 0.5% Proparacaine HCI, and IOP readings were taken using a TonoPen XL electronic aplanation tonometer (Mentor 0 & 0, Inc., Norwell, MA). The tonometer was calibrated each day prior to the procedure according to the manufacturer's instructions. Sample Collection. Hematology and Clinical Chemistry : Blood samples (~1 ml in EDTA and -2 ml with no anticoagulant) were drawn from a femoral vessel on day 0 (prior to dosing) and at necropsy. The hematology assessment included red and white blood cell counts, hemoglobin, hematocrit, red blood cell indices, platelet numbers, and a leukocyte differential. Clinical chemistry profiles included measures of chloride, bicarbonate, potassium, sodium, sodium/potassium ratio, blood urea nitrogen, creatinine, blood urea nitrogen/creatinine ratio, total bilirubin, direct and indirect bilirubin, glucose, total protein, albumin, globulin, albumin/globulin ratio, calcium, phosphorus, alkaline phosphatase, alanine amino transferase, aspartate amino transferase, gamma-glutamyl transferase, creatine phosphokinase (CPK), cholesterol, and triglycerides. Plasma Samples: Blood samples (~1 ml in EDTA) were drawn from a femoral vessel on day 0 (prior to dosing and 1 hr postdose) and daily thereafter. Following centrifugation at -3,000 X g for 10 min, the plasma was stored at --70°C until it was assayed for pharmacokinetics (analyte) and antibodies to the test materials (i.e., anti-analyte antibodies).
Vitreal Samples: Each animal was euthanatized with an intravenous overdose of pentobarbital, and a vitreous sample (0.02 to 0.12 ml) was collected from each eye using a 26-gauge needle, as described for intravitreal injection. The vitreous was replaced by injecting an equivalent volume of fixative. Each vitreal sample was stored at --70°C until it was assayed for pharmacokinetics and antibodies to the test materials. Tissue Samples: Immediately subsequent to vitreal sampling, both globes (with optic nerve) were carefully removed from the orbits. Excess tissue was trimmed from each eyeball, and the eyes were immersion fixed in 10% neutral-buffered formalin or Zenker's solution for 24 hr and were then transferred to 70% ethanol. The carcass was discarded without further evaluation. Globes were trimmed into superior, middle, and inferior calottes (21) , and sections from the middle calotte were processed for microautoradiography using standard techniques (12) . For each globe, 1 hematoxylin and eosin-stained section and 3 microautoradiographic exposures were made. Representative photomicrographs showing the distribution of silver grains at each time point were taken with darkfield illumination on a Leitz Diaplan microscope using Kodak 160T Extachrome film at a reciprocity of 1.
Quantitation and Characterization of Radiolabeled Test Materials in Vitreous and Plasma. TCA precipitations were performed on vitreous and plasma samples. For vitreous, 25 jjd of vitreal fluid was added to 125 fed of phosphate-buffered saline containing 0.5% bovine serum albumin/0.01 % Tween-20. One hundred-fifty )Jd of 20% TCA was added, and the tubes were vortexed. For plasma, 100 >1 of plasma was placed in micronics tubes, 100 jjbl of 20% TCA was added, and the tubes were vortexed. After a 60-min incubation at 4°C, the tubes were centrifuged at 10,000 X g for 5 min. Total counts per minute (cpm) in each tube were measured in a LKB gamma counter (Gaithersburg, MD) set for a 500-(jd window and counted for either 1 (vitreous) or 10 min (plasma). Supernatants were removed by vacuum aspiration, and the pellets were counted under the same conditions. Per-cent TCA precipitability was calculated as (cpm pellet + cpm total) X 100. In addition, sodium dodecyle sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) was performed on vitreal samples in 4-20% gradient polyacrylamide gels (Integrated Separation Systems, Natick, MA). Samples were prepared in SDS sample buffer, with and without dithiothreitol as a reducing agent.
Enzyme-Linked Immunosorbent Assay for Analyte and Antibodies to Test Materials. rhuMAb HER2 Pharmacokinetic Samples: Vitreal fluid from each eye and plasma from animals receiving 125 I-rhuMAb HER2 were assayed in an enzyme-linked immunosorbent assay (ELISA), which uses HER2 extracellular domain for capture and goat anti-human IgG F(ab' )Z HRP (Organon Teknika Corp., Durham, NC) for detection. The lower limit of detection was 3.1 ng/ml, following a minimum 1:10 dilution in assay buffer.
rhuMAb VEGF Fab Pharmacokinetic Samples: Vitreal fluid from each eye and plasma from animals receiving 125 I-rhuMAb VEGF Fab were assayed in an in-house rhuMAb VEGF ELISA, which uses full-length VEGF165 (containing both the receptor-binding and heparin-binding domains) for capture and goat anti-human IgG Fab HRP (Organon Teknika Corporation, Durham, NC) for detection. The lower limit of detection using full-length VEGFI6s was 7.8 ng/ml, following a minimum 1:10 dilution in assay buffer. Plasma samples were reassayed on plates coated with truncated VEGFs-109 (i.e., VEGF consisting of amino acids 8-109, which is the receptor-binding domain only) in order to rule out assay interference due to endogenous (heterophilic) antibody interactions with the heparin-binding domain of VEGE The lower limit of detection in the truncated VEGF assay was 16 ng/ml, following a minimum 1:10 dilution in assay buffer. Detection of Antibodies to rhuMAb HER2: Vitreal fluid from each eye and plasma from animals receiving lzsl-rhuMAb HER2 were assayed in an in-house human antihuman antibody (HAHA) HER2 Fc ELISA and the HAHA HER2 Fab ELISA. The sensitivity of these assays was 2 log titer units, following a minimum l:100 dilution in assay buffer.
Detection of Antibodies to rhuMAb VEGF Fab: Vitreal fluid from each eye and plasma from animals receiving l2sl_rhuMAb VEGF Fab were assayed in a rhuMAb VEGF Fab antibody ELISA. The sensitivity of this assay was 1.7 log titer units, following a minimum 1:50 dilution in assay buffer.
Pharmacokinetics of the Test Materials in the Vitreous
Fluid: The pharmacokinetics of rhuMAb HER2 and rhuMAb VEGF Fab in vitreous fluid were estimated by fitting an exponential function (i.e., C(t) = As'&dquo;*) to the immunoreactive rhuMAb HER2 and rhuMAb VEGF Fab concentration (C) versus time (t) data for vitreal samples. The data were weighted by 1/y2, where y is the observed concentration. Derived pharmacokinetic parameters (i.e., clearance, volume of distribution, mean residence time, and half-life) were computed from the parameters of the function, C(t) (24) .
Pharmacokinetics of the Test Materials in the Plasma: rhuMAb VEGF Fab concentrations in plasma were consistently below 7.8 ng/ml (i.e., the assay limit of detec-tion) ; therefore, no further analyses were performed on these data.
The concentrations of rhuMAb HER2 in plasma represent a balance between the input and elimination processes ; because these data cannot be analyzed outside the context of a model that incorporates specific input and elimination information, a model was constructed to describe the transport of the rhuMAb HER2 from the vitreous to the plasma, using historical intravenous pharmacokinetic data for rhuMAb HER2 in Rhesus monkeys (Genentech, Inc., data on file). This model is illustrated as follows:
The dose (25 >gleyej 50 [Lg total) is injected into the vitreous Xo, and the variables X1 and X2 represent the amount of the drug in the plasma compartment and other exchanging systemic compartments, respectively. The measured concentration in vitreous is Xo/Vo, where Vo is the volume of distribution in the vitreous compartment. This volume is a parameter that has to be identified, in addition to the rate constants roi and roo. The rate constant roo represents the irreversible loss of test material from vitreous that does not enter the plasma compartment;
from these values, the fraction of the dose that reaches the systemic circulation is calculated as (rol/(roo + ro,)). The measured concentration in plasma is X1/V,, where V is the volume of distribution in the plasma compartment. This volume and the rate constants rio, r12, and r2l were computed from the exponential fitting of a previous intravenous pharmacokinetic study in Rhesus monkeys; these values were used as fixed parameters in the estimation routine. The vitreous and plasma data were weighted 1/y2, where y is the observed concentration.
Estimation Procedures: Exponential components and the model parameters were estimated by a nonlinear least-squares method using the Gauss-Newton-Marquardt-Levenberg procedure (19) . The model differential equations were solved numerically by the fourth-order Runge-Kutta method. The search routine was implemented on a Dell 450DE PC running HTBasic (HTBasic 386 for PC, TransEra, Provo, UT). Nominal sample collection times and doses were used in the analyses.
RESULTS
All animals completed the study. Body-weight gains and food consumption were within normal limits, except for those associated with 1 animal in the rhuMAb VEGF Fab group (detailed below). Immediately following intravitreal injection, IOP increased markedly (3to 7-fold) in all animals, but it decreased to baseline levels within 1 hr. Other ophthalmologic findings and the clinical observations for all of the rhuMAb HER2 animals and for 4 of 5 rhuMab VEGF Fab animals were within normal limits during the 14-day observation period. One rhuMAb VEGF Fab animal developed acute intraocular inflammation 5 days postinjection. At necropsy (day 7), moderate to severe aqueous flare was observed in both anterior chambers, and neither fundus was visible by direct ophthalmoscopy. Relative to baseline, this animal had a 0.2-kg weight loss, elevated white blood cell count (which was, nevertheless, still within the normal reference range), and low IOP Ocular inflammation in this animal was considered to be secondary to the injection procedure itself rather than directly related to test material, since none of the other animals receiving rhuMAb VEGF Fab were similarly affected.
Antibody titers in all plasma and vitreal samples were below the limit of assay detection for both treatment groups. Hematology and clinical chemistry values for all animals were within normal reference ranges, except for serum CPK, which was elevated in samples collected on days 0 through 4. This elevation was attributed to intramuscular administration of ketamine and physical restraint for dosing on day 0. CPK values returned to baseline by day 7.
Microautoradiography
The distribution of 1211-labeled rhuMAb HER2 and rhuMAb VEGF Fab in the retina was evaluated by microautoradiography ( Fig. 1 ). With this technique, the labeled test material exposed silver grains in the overlying emulsion; the location of these silver grains, as detected by light microscopy, was used to determine the tissue distribution of the test material.
At the 1-hr time point, patchy aggregates of rhuMAb HER2 were observed in the vitreal compartment but were not present adjacent to the retina (Fig. 1 ). By day 1, accumulations of labeled material were observed at the inner limiting membrane (ILM), the outermost retinal layer at the vitreal-retinal junction. Microautoradiographic signal at the ILM was maximal at days 1 and 4 but persisted at this site through the day 14 time point. rhuMAb HER2 did not penetrate the ILM into deeper retinal layers at any of the time points examined.
In contrast, rhuMAb VEGF Fab was distributed throughout the retina as early as 1 hr postdose ( Fig. 1 ). At this time point, microradiographic signal in the medial and lateral portions of the retina was present in all retinal layers, including the retinal pigment epithelium (RPE) adjacent to the choroid, whereas in the posterior retina, labeled material extended only as far as the outer nuclear layer (ONL). The retarded movement of test material in the posterior retina reflected differences in diffusion distances attributable to the increased thickness of the nervefiber layer in the region of the optic nerve. This delayed diffusion was only transient, since rhuMAb VEGF Fab was uniformly distributed in all retinal layers at days 1 and 4. Microautoradiographic signals for rhuMAb VEGF Fab in the retina were maximal at day 1, but in contrast to rhuMAb HER2, they did not persist beyond day 7 and were at background levels by day 14. Although the animal at the day 7 time point had severe acute bilateral suppurative endophthalmitis, diffusion of labeled material in the retina did not appear to be affected, since maximal retinal penetration (all retinal layers) was already achieved by the day 1 time point. Movement of both full-length rhuMAb HER2 and rhuMAb VEGF Fab from the vitreous to the posterior and anterior chambers was observed on days 0 (1 hr), 1, and 4 but was not observed at the subsequent time points.
This transfer was consistent with the known movement of substances between the vitreous and aqueous (11) and the directed outflow of aqueous from the posterior to the anterior chamber and into the venous circulation (22) .
Phannacokinetics of rhuMAb HER2 and rhuMAb VEGF Fab in the Vitreous
The pharmacokinetics of immunoreactive rhuMAb HER2 (Fig. 2 ) and rhuMAb VEGF Fab (Fig. 3 ) in the vitreous were well described by a single exponential (pharmacokinetic analyses based on radioactivity produced similar results-data not shown). The estimates of the parameters of the function are provided in Table I. The half-lives of rhuMAb HER2 and rhuMAb VEGF Fab in the vitreous were 5.6 and 3.2 days, respectively, whereas the volumes of distribution were similar (-5 ml/ eye). Vitreal samples showed approximately 99% TCA precipitability over the course of the study. SDS-PAGE gels from both groups showed no signs of complex formation or degradation of the samples over the time course of the study. The vitreal samples looked identical to the radiolabeled dose material on the gels. For vitreal samples from the rhuMAb HER2 animals, radiolabeled material on the nonreduced gels showed a molecular weight of approximately 150 kD, which is consistent with the known molecular weight of rhuMAb HER2 (i.e., 148 kD). Upon reduction, the observed molecular weight was approximately 48 kD, which is consistent with expected values for a reduced antibody. For vitreal samples from the rhuMAb VEGF Fab animals, the radiolabeled material on the nonreduced gels showed a molecular weight of approximately 48 kD. This value did not change upon reduction, which is consistent with expectations for a Fab antibody.
Concentrations of rhuMAb HER2 and rhuMAb VEGF
Fab in the 1-hr vitreal samples were very low in comparison with those from the subsequent time points; these data were not included in the analysis. The low concentrations at this time point probably represented incomplete mixing of the 50-jjd dose in the vitreous compart- Based on data from a pharmacokinetic study in Rhesus monkeys following a single intravenous dose of 500 ~Lg/kg (Genentech, Inc., data on file). ment prior to sacrifice, exacerbated by the small sample volume (0.20-0.12 ml) that was collected. By 24 hr, dose material is well mixed in the vitreal compartment (J.
Mordenti, unpublished observations), and samples collected from day 1 onward were considered representative of concentrations throughout the vitreous compartment. The concentration of rhuMAb VEGF Fab in the day 7 vitreal sample (Fig. 3 ) was not used in the data analysis because this animal had clinical and histopathologic evidence of acute intraocular inflammation, which might have altered the integrity of the blood-retinal barrier (15) .
A Pharmacokinetic Model to Simultaneously Describe
Vitreal and Plasma rhuMAb HER2 Data rhuMAb HER2 plasma concentrations in 3 animals were below the limit of detection in the ELISA (<3.1 l ng/ml), whereas the remaining 2 animals (euthanatized on days 1 and 14) had very low plasma concentrations (i.e., 8.9 to 20.25 ng/ml). The volume of vitreous Vo and transport rate coefficients roi and roo were estimated, whereas the parameters in Table II (which characterize the plasma pharmacokinetics) were kept fixed. These results are shown in Fig. 4 and are reported in Table III . The systemic bioavailability is approximately 30% in this one animal (if we assume a plasma concentration of 3.1 l ng/ml throughout the study, systemic bioavailability would be less than 4% in the other animals), and the volume is again estimated to be ---5 ml/eye. There are large errors associated with the estimation of r01 and roe. errors that are attributable to the noise and insignificant slope of the plasma concentration versus the time data. Furthermore, these 2 parameters are highly correlated. Naturally, these analyses depend on how well the historical rhuMAb HER2 pharmacokinetic data represent the rhuMAb HER2 plasma pharmacokinetics in the present study as well as on the influence of the inter-and intraanimal variability on the intravitreal pharmacokinetics.
Radioactive counts (total cpm/ml) in the plasma samples from both groups were low; consequently, TCA precipitability was quite variable, particularly in the plasma samples from the rhuMAb VEGF Fab group. Since a Fab antibody fragment is cleared/metabolized faster than a full-length antibody (20) and because rhuMAb VEGF Fab readily penetrated the retina, the lower amount of plasma radioactivity and the greatly reduced TCA precipitability in the Fab group are not unexpected results.
DISCUSSION
Intravitreal administration of rhuMAb HER2 and rhuMAb VEGF Fab were well tolerated. Overall, direct ophthalmoscopic examinations, terminal IOP readings, and hematology and clinical chemistry values were unremarkable. One rhuMAb VEGF Fab animal had weight loss, low IOP, elevated white blood cell counts, and acute ocular inflammation, which was attributed to the injection procedure. CPK values were elevated in animals on days 0 to 4 secondary to physical restraint and intramuscular injection of ketamine prior to dosing.
The intravitreal route of administration has the potential to deliver antibodies directly to the retina, thus limiting systemic exposure and decreasing material requirements, compared with intravenous administration. Systemic exposure to full-length antibody was variable among animals, ranging from <4% (indeterminable) to 30%, whereas animals receiving Fab antibody did not have any detectable material in the plasma. Microautoradiography demonstrated that while the full-length antibody did not penetrate beyond the ILM of the retina, the Fab antibody rapidly diffused to the RPE layer and persisted at least until day 7. The absence of measurable concentrations of rhuMAb VEGF Fab in the plasma may reflect limited transport from the vitreous to the circulation (i.e., concentrations less than 7.8 ng/ml at all time points), rapid clearance of any test material that did reach the bloodstream, intraocular tissue uptake/binding, or any combination of these 3 factors.
The volumes of distribution for the 2 antibodies in vitreous were similar (approximately 5 ml); however, these volumes are considered large in relation to true vitreous volume (approximately 1.5 ml). A possible explanation for this discrepancy is that a good estimate for t = 0 was not obtained because of incomplete mixing in the gelat- Table II. inous vitreous compartment at the initial time point (i.e., Full-length rhuMAb HER2 is cleared slowly from the vitreous compartment. The half-life (5.6 days) is similar to the value reported in rabbits for the same test material (i.e., 5.6 days; 16) . rhuMAb VEGF Fab is cleared more rapidly from the vitreous fluid (half-life, 3.2 days), reflecting the smaller size of the Fab antibody fragment (48 kD) compared to the full-length antibody (148 kD). In the literature, additional data for albumin (-67 kD; 14) supports our conclusions that molecular size influences the rate of removal from the vitreous. In that study (14) , the half-life for 131I-albumin (rabbit origin) in albino rabbits was 4.3 days, midway between the half-life for the anti-VEGF Fab and the intact anti-HER2 antibody in our study. Furthermore, the pharmacokinetics and half-life of full-length murine anti-VEGF antibody A4.6.1 and an anti-gpl20 isotype control antibody were similar when compared in rabbits (dose = 20 ~g/eye) and dogs (dose = 300 >gleye) (L. Berleau, unpublished observations), which suggests that the presence of a specific ligand does not influence the intraocular pharmacokinetics at these doses.
Using microautoradiography, the Fab antibody rapidly diffused deep into the retina, which may have contributed to its more rapid clearance from the vitreous. At the 1hr time point, diffusion of the Fab was greater in the peripheral regions of the retina (i.e., RPE) compared with the posterior retina near the optic nerve (i.e., outer nuclear layer). In this region, the retina is thicker because of expansion of the nerve-fiber layer, which suggests that distance may be a factor in the rate of diffusion at this time point. However, this difference was absent in subsequent time points (days 1, 4, and 7), where the Fab was distributed throughout the retinal layers, extending to the RPE in all regions. The apparant accumulation of rhuMAb VEGF Fab in the RPE suggests that Bruch's membrane may act as a barrier to further diffusion (i.e., into the choroid) in the healthy eye. In contrast, the fulllength antibody did not penetrate beyond the ILM of the retina at any of the time points examined.
This study was conducted in order to assess the effects of molecular size (rather than specific epitope binding) on retinal penetration. The selection of the full-length and Fab antibodies that were used in this study was based upon their relative size (148 and 48.3 kD, respectively), the availability of test material, and the availability of assays. Although the retinal distribution of the epitopes for the full-length and Fab antibodies (HER2 and VEGF, respectively) that were used in this study differed (3, 17, 18) , excess unlabeled material was included in the dosing solution in order to eliminate epitope-specific high-affinity binding, thus allowing for the unrestricted retinal diffusion of labeled material over time. This movement of labeled test material through the retina is influenced by the effects of molecular size and physical barriers rather than by highaffinity interactions. For example, in this study, the ILM represents a barrier to diffusion of an intact antibody rather than a specific target for antibody binding. In addition, when full-length murine anti-VEGF was compared to anti-VEGF Fab in rabbits in an identical study design (20 Rg protein, [9] [10] RCi, in 50 ~1 for each eye), similar retinal tissue distribution was observed (A. Ryan, unpublished observations), thus confirming that ligand binding has less influence than does molecular size on tissue penetration at these doses. These findings are consistent with a published report on the distribution of electron-dense particles (thorium dioxide and ferritin) following intravitreal administration in the cat (23) . These particles, with an approximate diameter of 100 A, appeared at the inner plexiform layer at 1 hr and at the external limiting membrane at 6 and 24 hr postdose, with tissue penetration deepest in the peripheral regions of the retina. Since thorium dioxide and ferritin are midway in size between an intact antibody (150 X 120 A) and a Fab antibody fragment (80 X 50 A) (L. Presta, personal communication), tissue penetration appears to be inversely correlated with size. Thus, size rather than specificity for a certain epitope appears to be the critical factor in the extent of retinal diffusion following intravitreal antibody administration. Further, it appears that the molecular-size cutoff for retinal penetration (in a healthy eye) is between 100 and 150 A.
The differences in pharmacokinetics and tissue distribution that are noted between the full-length and Fab antibodies in this study identify potential therapeutic approaches that may be exploited in specific disease conditions. For example, intravitreal administration of a Fab antibody, which rapidly diffuses through the retina to the retinal-choroid junction, might be useful in the treatment of AMD, which is characterized by the invasion of choroidal capillaries into the retina. In contrast, full-length antibodies might be more useful therapeutics in the treatment of proliferative retinopathies, such as PDR and retinopathy of prematurity, since pathologic neovascularization is present at the vitreal-retinal junction, and full-length antibodies do not penetrate beyond this interface. Pharmacokinetic differences could be exploited in order to provide either short-acting or sustained local concentrations, depending on the specific protein and disease condition. For instance, it may be possible that an intact antibody can be administered intravitreally every 1 to 2 mo and a Fab antibody fragment can be administered intravitreally every 2 to 4 wk in order to provide sustained concentrations. If longer dosing intervals are desired, novel formulations (such as poly(laetic-co-glycolic acid) [PLGA] microspheres) may be considered.
